ANL vs AURA
Side-by-side comparison of price performance, valuation, growth, profitability, analyst targets and technical trend.
ANL · Adlai Nortye Group$10.28 ▲ 6.20%
AURA · Aura Biosciences$6.56 ▲ 3.47%
One year, rebased to 100
Each line starts at 100 so growth is directly comparable
- ANL +550.6%
- AURA +18.8%
Head to head
| Metric | ANL | AURA |
|---|---|---|
| Price | $10.28 | $6.56 |
| Change today | ▲ 6.20% | ▲ 3.47% |
| Market cap | $662.01M | $680.30M |
| Return, 3 months | -22.3% | -14.8% |
| Return, year to date | +623.9% | +20.4% |
| Return, 1 year | +563.2% | +22.6% |
| P/E (TTM) | – | – |
| P/B | 3.1 | 2.2 |
| P/E percentile vs own 5y | 4th | 76th |
| Dividend yield | – | – |
| Revenue growth (YoY, latest qtr) | – | – |
| Net profit growth (YoY) | -1,715.5% | -68.9% |
| Gross margin | – | – |
| Operating margin | -123.5% | – |
| Net margin | -124.8% | – |
| Return on equity | -20.2% | -53.5% |
| Analyst target vs. price | +199.6% | +212.5% |
| Analyst buy share | 100% | 100% |
| RSI (14) | 40 | 54 |
| 30-day volatility | 95.1% | 45.5% |
| Max drawdown, 1 year | -45.7% | -32.6% |
| Trend read | Leaning bearish | Leaning bullish |
| Analyst consensus | Buy | Buy |
Green cells mark the best value in each row where "better" is clear-cut (lower P/E, higher margin). That is a reading of the numbers, not a recommendation. Financials are in each company's reporting currency.
What the numbers say
- AURA is the largest of the group by market value.
- ANL has returned the most over the past year.
- AURA has been the calmest stock over the last 30 days.